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Although cutaneous T-cell lymphoma (CTCL) is a neoplas-
tic helper T-cell disorder of unknown etiology, prolonged 
antigenic stimulation has been postulated to contribute to the 
development of this disease. Because Epstein-Barr Virus 
(EBV) infection has been associated with several different 
lym phomas, the sera of21 CTCL patients were examined for 
antibodies to EBV antigens . By using complement immuno-
fluorescence (CIF) techniques, 13 of 21 CTCL patients had 
detectable antibodies to Epstein-Barr Nuclear Antigens 
(EBNA), whereas only five of 20 control psoriatic patients 
were elF positive. When immunoblot analysis was em-
ployed, all 21 of the CTCL patients had antibodies to the 
C utaneous T-cell lymphoma (CTCL) is a neoplastic disorder of CD4+, 4B4+ (helper/memory) T-cells [1-4]. Although the cause of this neoplasm is un-known, it has been speculated that chronic antigenic stimulation might contribute to the development of 
CTCL f2,5] . Epstein-Barr virus (EBV) is one of the most common 
viral infections [6]. EBV may remain in a latent state for years but 
also has the capability to serve as a tumor agent, as has been shown 
for Burkitt's lymphoma and nasopharyngeal carcinoma (NPC) [7 -
9]. Recently, EBV gene products have been found in tissues ob-
tained fromlatients with Hodgkin's disease, non-Hodgkin's lym-
phomas, an certain T-cell lymphomas [10-14]. These findings 
prompted us to consider whether EBV infection might have an 
etiologic role in the development of CTCL. 
Following an EBV infection antibodies are produced against var-
ious EBV products, including early antigens (EA), viral capsid anti-
gens (VCA) , Epstein-Barr - associated nuclear antigens (EBNA), 
and rheumatoid arthritis nuclear antigen (RANA) [15] . The pres-
ence of antibodies to the.se antigens is determined by several differ-
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anci-EBNA: anti - Epstein-Barr nuclear antigen 
CIF: complement immunofluorescence 
EBV: Epstein-Barr virus 
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EBV antigens, EBNA, whereas only 12 of the control pa-
tients had detectable antibodies to these antigens. In ad-
dition, three of 21 CTCL patients had antibodies to the 
EBV-associated antigen, rheumatoid arthritis nuclear anti-
gen (RANA) , as determined by double immunodiffusion, 
whereas none of the control sera contained anti-RANA anti-
bodies. These results indicate that antibodies against EBV 
antigens are found with a higher frequency and concentra-
tion in patients with CTCL when compared to controls and 
suggest that EBV products might serve as a possible stimulus 
for the development of this malignant disease.] Invest Derma-
toI95:309-312,1990 
ent techniques including indirect immunofluorescence for EA and 
VCA, complement immunofluorescence (CIF) for EBNA, and 
double immunodiffusion for anti-RANA antibodies [15 -17]. More 
recently, immunoblot analysis has been employed to identify the 
viral peptide specificity of each antibody [18- 20] . In this report, we 
demonstrate that each of the 21 CTCL patients had antibodies to 
EBV products. These results suggest that EBV antigenic stimulation 
might be one possible factor which contributes to the development 
ofCTCL. 
MATERIALS AND METHODS 
Patients and Sera Sera were obtained from 21 CTCL patients 
with plaques and nodules (16 male, five female) who were between 
the ages of 36 and 82 years. Sera from 20 patients with widespread 
psoriasis were used as controls. Serum samples from the CTCL and 
psoriatic patients were screened for the presence of antibodies to EB 
virus products by complement immunofluorescence, double im-
munodiffusion, and immunoblot analysis. 
Cells WiL2 cells, an Epstein-Barr virus-transformed human B 
lymphocyte cell line, were used in this study [21]. Non-EBV asso-
ciated tumor HEp-2 cells and normal human lymphocytes were 
used as control s. All cells were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum, minimum esential me-
dium (MEM)-non-essential amino acids, MEM-vitamins, sodium 
pyruvate, antibiotics, and 2 mM glutamine (Gibco, Buffalo, New 
York). Each cell type was used as a substrate for complement immu-
nofluorescence analysis. Extracts from these cells also were used in 
immunodiffusion and immunoblot analysis. 
Cytospin Slide Preparation WiL2 cells, HEp-2 cells, and nor-
mal human lymphocytes (106 cells/ ml) were centrifuged onto clean 
slides using a Shandon Cytocentnfuge. The slides were fixed in 
acetone at room temperature for 10 min and then kept at -70·C 
until used. 
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Cell-Extract Preparation An equal amount of phosphate-buf-
fered saline containing 1 mM phenylmethylsulfonylfluoride was 
added to packed ce ll pellets (1 X 109 / ml) . The cell suspension was 
disrupted using an u ltrasonicator. The supernatants, after clarifica-
tion with centrifugation (20,000 X g/30 min) , were then used as 
antigens in immunodiffusion and immunoblot examination. 
Com plement Immunofluorescence (ClF) Complement im-
munofluorescence (CIF), as described earlier, was used to determine 
anti -Epstein-Barr Nuclear Antigen (EBNA) antibody activity [22]. 
WiL2 cell s, which are known to contain EE virus genotDe, were 
used for screening for the presence of presumptive anti-EBNA anti-
body [1 7,22). HEp-2 cells, which do not contain EB virus genome, 
were used as negative controls for anti-EENA. 
D etection of anti-RANA Antibody Double immunodiffusion 
usi ng W iL2 cell extracts as an antigenic source was used to detect 
the presence of anti-RANA antibodies. T he specificity of these anti-
bodies was determined by using reference sera to Sm, nRNP, SSA/ 
Ro, SSE/La, and RANA antigens [1 6,17]. Extracts from HEp-2 
cells and 110rmallymphocytes served as negative controls. 
Imm unoblot Assay Protein immunoblot method was used to 
de tect peptides recognized by anti-EEV antibody [18,1 9,23). The 
antigenic sources for the detection of autoantibodies included ex-
tracts of WiL2 cells, HEp-2 cell s, and lymphocytes from normal 
healthy donors. In addition , the precipitin lines in double immuno-
diffusion plates were eluted and used as antigens. 
RESULTS 
Presence of Anti-EBNA Antibodies in CTCL Patients The 
presence of anti-EENA antibodies in CT CL patients was deter-
mined by C IF using WiL2 cells as the substrate. HEp-2 cells, which 
lack EE virus genome, were used as controls. Sera from 13 of 21 
CT CL patients gave positive ClF staining on WiL2 cells at a dilu-
tiori of 1 :40, whereas onl y five of 20 control psoria tic patients had 
detectable anti-EBNA antibodies at this dilution. Sera from 5 
CT C L pati ents continued to have positive ClF reactivities at a dilu-
tion of 1: 160, whereas only 1 control patient had detectable anti-
EENA antibodies at this dil ution (Table I) . All 21 sera samples from 
the CT C L patients gave negative C lF staining on EBV-negative 
HEp-2 cells. Representative positive and negative C IF staining of 
WiL2 and HEp-2 cells, respectively, are shown in Fig 1. These 
fi nd ings indicate that CT CL patients have a higher frequency and a 
higher titer of anti-BEY antibodies . 
Immunoblot Analysis When WiL2 cell extracts were used in 
immunoblot analysis, a 1: 100 dilution of sera from each of 21 
CT CL patients showed similar reactivity. Antibodies from each 
patient identified two peptides with molecular weights (Mw) of 
between 75 and 90 kD. The results of immunoblot analysis are 
listed in T able I and demonstrated in Fig 2. Lane 1 of Fig 2 illustrates 
the two peptides recognized by serum from CT C L patients. These 
peptides are simi lar to those identified by positive control serum 
obtained from a patient known to have anti-EENA antibodies (Fig 
2, la'"le 2). Similarly, the immune complexes isolated from a precipi-
tin line formed by a CT CL patient' s antibodies to RANA were 
found to contain the same two peptides, as show n in lalle 3. Control 
Table I. Frequency of Antibodies to EENA in the Serum of 
CT CL and Control Psoriatic Patients 
Cl F' 
Immunoblot 
Sera Dil ution 
1 : 40 
1: 60 
1: 100 
• C1F: Complement immunoflu orescence. 
Number of 
Pos itive Patient Sera 
13 of 21 CT CL 
5 of 20 Psoriasis 
5 of2 1 CT C L 
1 of 20 Psorias is 
21 of 21 CTCL 
12 of 20 Psoriasis 
T HE J OU RNAL OF INVESTIGATIVE DERMATOLOGY 
A 
B 
Figure 1. Complement immunofluorescence staining on W iL2 cell ~ 
H Ep-2 cell substrates. Cytoplasmic staining is due to Evans Blue coun£tt, 
staining. A, Positive speckled nuclear stain ing by one CT C L patient s~ 
on WiL2 cell substrate (magnification X 1500); B, Negative staining b ' til, 
same CT C L pa tient seru m on H Ep-2 cel l substrate (magnifica rion X 1500~ 
immune complexes iso lated from a different precipitin line did n ' 
contain these 85-kD and 80-kD peptides, as shown in lalle 4. Th _ 
tw.o peptides have the expected mws of EBNA [24J . No EBV anti.-
gens were detected in extracts from HEp-2 cells, rabbit thymus, an 
normal hliman lymphocytes (fi g 2, lalle 5 and 6). Anti-EBNA anti, 
bodies also were found in the sera of 12 of 20 psorias is con 
patients using immuhoblot analysis (Table I) . Using the more sp<" 
cific immunoblot assay, these findings confirm and extend the posi-
tive resu lts of the screenin g C IF assay for EBV serology. 
The Presence of Anti-Rheumatoid Arthritis Nuclear Anti, 
gen (Anti-RANA) Antibodies in CTCL Patients T he pm, 
ence of anti-RANA antibodies in the sera of CT C L patients \\~ 
analyzed by double immunodiffu sion using anti-RAN A positi~ 
reference sera and a WiL2 cell extract as the antigenic source. Th~ 
of 21 CTCL patients were anti-RANA positive, whereas none ~ 
our 20 psoriatic patients had anti-RAN A antibodies. 
DISCU SSIO N 
This study demonstrates an increased prevalence of antibodie . 
CTCL patients to Epstein-Barr virus (EBV) products. EBV infee, 
tion normally elicits antibodies against at least three sets of EB\' 
products: EA, VCA, and EBNA. T he presence of anti-EBNA an . 
bod ies has previously been detected solely by complement imrnun 
fluorescence on EBV transformed cell substrates such as Raji cell«, 
P3HR 1 cells as well as other cell lines (7 ,22,24]. Recently, imm 
oblot analysis has been employed to determine the fine speCificity 
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Figure 2. Protein immunoblot analysis using different sources of antigen 
and sera from CTCL and positive control (RA) patients. Lalles 1 alld 2: 
peptides of molecular weight of 80 and 85 kD were recognized by serum 
from a CTCL patient and anti-EBNA positive RA patient respectively. The 
EBV positive WiL 2 extract was used as the antigel1ic source. Lalle 3, peptides 
of the same molecular weight were also found in immune complexes ob-
tained from the anti-RANA precipitin line in double immunodiffusion. The 
other bands were human immunoglobulin as also seen in Lalle 4, which was 
from a precipitin line other than anti-RANA. Lalles 5 atld 6: extracts ofEBV 
negative HEp-2 cells and human lymphocytes, respectively, were used as 
mrigenic source and no peptide bands were bound by patient sera. 
each antibody. In our study, 62% of CTCL patients were found to 
have anti-EBNA antibodies by CIF at a 1:40 serum dilution, versus 
25% of the psoriatic control patients. Five of the CTCL continued 
to have detectable antibodies to EBNA at a serum diluation ofl:160. 
EBNA has been shown to be composed of several polypeptides of 
molecular weights ranging from 40 kD to 140 kD. There are five 
known EBNA, which are numbered EBNA 1-5 [18-20,24-32J. 
EBNA 1 appears to be required for maintenance of the virus in 
episomal form and is defined as the product of the Bam HI-K 
fragment [28J . Its MW has been reported to be approximately 75 
kD [18,24-28,32J. EBNA 1 is present in EBV transformed cells 
such as WiL2, Raji, and JA cells. EBNA 2 has been recently assigned 
to the Bam H 1-WYand H region, and has a MW of 80 to 90 kD 
[18,19,24-27,32J. Both EBNA 1 and EBNA 2 are associated with 
latent infection and transformation, but neither antigen can be de-
tected in cells recently infected with EBV. Antibodies to EBNA 1 
and EBNA 2 are best detected by immunoblot analysis and an en-
zyme- linked immunosorbent assay. In this study, all 21 of the 
CTCL patients had demonstrable antibodies to both EBNA 1 and 
£BNA 2, the presence of which indicates prior EBV infection. 
Three additional EBNA antigens (EBNA 3, EBNA 4, and EBNA 5) 
also have been identified. EBNA 3 is a polypeptide with a MW of 
140 kD and is found only in latently infected cells or EBV-trans-
formed cells [29,30J . EBNA 4 is a larger antigen with a MW of150 
to 180 kD, whereas EBNA 5 is a much smaller nuclear protein (40 
to 70 kD) that is associated with EBV transformation [1 8,31 J. The 
incidence of antibodies to EBNA 3, EBNA 4, and EBNA 5 in 
patients infected with EBV is much lower than those for EBNA 1 
and 2, representing only 25% to 30% of all anti-EBNA positive sera. 
The clinical significance of antibodies to EBNA 3-5 remains to be 
elucidated. 
Anti-RANA antibody is a precipitin antibody that was initially 
fou nd in patients with rheumatoid arthritis [16,17]. The RANA 
antigen is present in EBV-transformed cells such as WiL2 and Raji 
cells. Using immunofluorescence staining, antibodies to RANA 
give a speckled nuclear pattern, indicating its nuclear localization 
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[1 6,17,25J. Thus, RANA is considered to be a member of the EBNA 
family. Anti-RANA antibodies are found in 50-80% of patients 
with rheumatoid arthritis, while a much lower incidence (0-25%) 
of these antibodies is reported in patients with other connective 
tissue diseases [16J . In our study, approximately 15% of CTCL 
patients had anti-RANA antibodies whereas none of our psoriatic 
patients had detectable anti-RANA activity. A correlation between 
antibodies to RANA and to EBNA as determined by CIF was ob-
served in our CTCL patients. All anti-RANA positive sera also had 
anti-EBNA CIF titers of 1 to 160 or greater. In addition, as shown in 
Fig 2, fall e 3, immune complexes isolated from an anti-RANA pre-
cipitin line contained two pep tides having molecular weights simi-
lar to the pep tides recognized by sera from CTCL or rheumatoid 
arthritis patients (Fig 2, falles 1, 2). This sUPforts the notion that 
RANA is a member of the EBNA family [25 . 
Although the significance of increased frequency and titers of 
anti-EBV antibodies in patients with CTCL is unknown, we specu-
late that EBV antigens could provide the stimulus which has been 
postulated to initiate CTCL. In order to gain more' insight into the 
possible role of EBV in the pathogenesis of CTCL, further investi-
gation is warranted. The antibody profi les of CTCL patients to 
various EBV antigens during the course of their disease need to be 
studied, because antibodies and titers to different EBV antigens have 
been shown to be valuable diagnostic and prognostic parameters in 
patients with NPC, Hodgkin's disease and non-Hodgkin's lym-
phoma [32,34,35J. For example, high titers ofEBV antibodies have 
been correlated with a poor prognosis in patients with Hodgkin's 
disease (anti-VCA) and non-Hodgkin's lymphoma (anti-EA) 
[34,35J. Conversely, anti-EBNA antibody levels are found to be 
significantly lower in patients with more extensive (stage III and 
IV) NPC [33J. Studies are in progress to investigate the diagnostic 
and prognostic application of antibody profiles to v;trious EBV 
products in our CTCL patients. It is hoped that these studies may 
provide insight into the pathophysiologic mechanisms responsible 
for CTCL and may lead to better treatments for patients with this 
disorder. 
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